MOPEAD - Models of Patient Engagement for Alzheimer's Disease

European Comission (H2020-JTI-IMI2-2015-05)

The MOPEAD project is a European initiative that aims to give citizens an active role in the early detection of Alzheimer's. For this reason, it studies the effectiveness of different participatory mechanisms.

Fundación ACE- Barcelona Alzheimer Treatment & Research Center has been selected by the IMI (Innovative Medicines Initiative) -a public-private partnership between the EU and the European Federation of Pharmaceutical Industries Associations (EFPIA)- to lead the MOPEAD project, a novel research that aims to consolidate an early diagnosis system for Alzheimer's disease.

The MOPEAD project (Models of Patient Engagement for Alzheimer's Disease) is a European initiative that aims to give citizens themselves an active role in the early detection of the disease. IMI will allocate 4 million euros to evaluate systems of patient involvement and participation that can be effective in the early diagnosis of the disease.

The aim of the MOPEAD project, according to its main researcher, Mercè Boada, is to raise awareness among citizens and increase their participation in the diagnosis. This will also help to identify unknown cases. The results will provide new clinical data on the disease in its early phase, which will contribute to the definition of novel therapeutic interventions to stop Alzheimer's.

For approximately 3 years, the research will test the effectiveness of diagnosing the disease in mild or earlier stages, in four models of citizen participation: an online questionnaire, the Fundació ACE Open Days, a 10-minute test conducted by primary care physicians and a neuropsychological test on patients diagnosed with type 2 diabetes, considered a risk factor for Alzheimer's disease.

The results of the MOPEAD will make it possible to identify and establish, at European level, the most appropriate model to facilitate access by citizens with slight cognitive impairment or memory complaints to a diagnosis of the disease at a very early stage.

Export to Europe the ACE early diagnosis model

One of the current challenges in this field is to make the apparently cognitively healthy population aware of the importance of knowing their mental performance and, in the event that they have subjective memory complaints or cognitive impairment, Alzheimer's can be detected, taking into account the importance of prevention and early diagnosis.

Fundación ACE, a pioneer in raising awareness for the promotion of early diagnosis, launched the Open Days in 2008. With the slogan If we look at blood pressure, cholesterol and sugar... Why not memory?, the Open Days are aimed at people over 55 years of age who voluntarily wish to have their memory, language and other cognitive functions assessed through the neuropsychological battery that Fundació ACE uses in the diagnostic process.

In addition to contributing to this model of citizen participation in the early detection of the disease, Fundació ACE coordinates this clinical research project in which some 2,000 people are participating.

The IMI (Innovative Medicines Initiative) is a public-private consortium (PPP) between the EU and the European Federation of Pharmaceutical Industries Associations (EFPIA) -the representative body of the pharmaceutical industry in Europe-. It was created in 2008 to boost pharmaceutical innovation in Europe and accelerate the development of more effective and safer drugs. With a budget of 2 billion euros, part of IMI's action is to support research projects that promote networks of industrial and academic experts. It aims to boost pharmaceutical innovation in Europe.

Data sheet

Start date


End date


Sponsors / Funders

IMI (Innovative Medicines Initiative) - public-private partnership between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA)


4.581.967,80 €

Project leader at Fundació ACE

Dr. Mercè Boada, co-founder and medical director


  1. Fundació ACE
  2. Eli Lilly Company Ltd
  3. ASDM Consulting
  4. AstraZeneca AB
  5. European Institute of Women's Health
  6. GMV Soluciones Globales Internet S.A.U.
  7. Karolinska Institute
  8. KITE Innovation (Europe) Ltd
  9. Spomincica-Alzheimer Slovenia
  10. Cologne University Hospital
  11. University Medical Centre Ljubljana
  12. Vall d'Hebron University Hospital Foundation-Research Institute
  13. Stichting VUmc
  14. Alzheimer Europe

Links of interest

Scientific publications

Patient Engagement: The Fundació ACE Framework for Improving Recruitment and Retention in Alzheimer's Disease Research. 
Journal of Alzheimer's Disease, vol. 62, no. 3, March 2018. doi: 10.3233/JAD-170866.
Boada, Mercè; Rodríguez-Gómez, Octavio; Alegret, Montserrat; Cañabate, Pilar; Lafuente, Asunción; Abdelnour, Carla; Morera, América; Sanabria, Ángela; Ruiz, Agustín; Tárraga, Lluís et al.

P3‐304: Models of Patient Engagement in Alzheimer's Disease (MOPEAD): a european multinational project to develop and test innovative patient engagement strategiesh. 
Alzheimer's Association International Conference: P3‐01: Poster Presentations, July 2018. doi:
Octavio Rodríguez-Gómez, Mercè Boada et al.

The MOPEAD project: Advancing patient engagement for the detection of “hidden” undiagnosed cases of Alzheimer's disease in the community.
Alzheimer's & Dementia. Volume 15, Issue 6, June 2019. doi:
Octavio Rodríguez-Gómez, Isabel Rodriguez, Montse Alegret, Sergi Valero, Mercè Boada et al.

A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease: Results from the MOPEAD Project.
Journal of Alzheimer's Disease 2021;83(3):1149-1159. doi: 10.3233/JAD-210303
Octavio Rodríguez-Gómez, Miren Gurruchaga Telleria, Sergi Valero, Mercè Boada et al.